TriangleDISEASE & TREATMENT SETTING
Idhifa: refractory acute myeloid leukemia with IDH2 stated without a specific alteration
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1 INDICATIONS AND USAGE IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ).
Broader topic: Acute Myeloid Leukemia
- Source population
- Not part of this definition
- Disease extent
- refractory
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- IDH2
- alteration
- stated without a specific alteration
- status
- present
- prior therapy
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Idhifa (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1 INDICATIONS AND USAGE IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ).
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice